Artemis Investment Management LLP Invests $8.02 Million in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Artemis Investment Management LLP bought a new stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 125,652 shares of the biopharmaceutical company's stock, valued at approximately $8,018,000. Artemis Investment Management LLP owned approximately 0.10% of Halozyme Therapeutics as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. D. E. Shaw & Co. Inc. raised its stake in Halozyme Therapeutics by 171.2% during the fourth quarter. D. E. Shaw & Co. Inc. now owns 831,414 shares of the biopharmaceutical company's stock worth $39,750,000 after purchasing an additional 524,802 shares during the period. Fifth Third Bancorp increased its holdings in shares of Halozyme Therapeutics by 29.4% during the 1st quarter. Fifth Third Bancorp now owns 10,017 shares of the biopharmaceutical company's stock worth $639,000 after buying an additional 2,276 shares during the last quarter. Charles Schwab Investment Management Inc. raised its position in shares of Halozyme Therapeutics by 0.6% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,783,177 shares of the biopharmaceutical company's stock valued at $85,254,000 after buying an additional 9,780 shares during the period. Farther Finance Advisors LLC lifted its holdings in Halozyme Therapeutics by 620.5% in the first quarter. Farther Finance Advisors LLC now owns 5,505 shares of the biopharmaceutical company's stock valued at $341,000 after acquiring an additional 4,741 shares during the last quarter. Finally, Two Sigma Advisers LP purchased a new position in Halozyme Therapeutics in the fourth quarter worth approximately $282,000. 97.79% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Halozyme Therapeutics

In other Halozyme Therapeutics news, Director Jeffrey William Henderson sold 4,497 shares of Halozyme Therapeutics stock in a transaction dated Monday, April 28th. The stock was sold at an average price of $60.37, for a total transaction of $271,483.89. Following the completion of the sale, the director directly owned 28,611 shares of the company's stock, valued at $1,727,246.07. The trade was a 13.58% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Helen Torley sold 20,000 shares of the stock in a transaction dated Tuesday, June 24th. The shares were sold at an average price of $53.73, for a total value of $1,074,600.00. Following the completion of the transaction, the chief executive officer owned 733,719 shares in the company, valued at approximately $39,422,721.87. The trade was a 2.65% decrease in their position. The disclosure for this sale can be found here. Insiders sold 44,497 shares of company stock worth $2,405,284 in the last three months. 2.90% of the stock is currently owned by corporate insiders.

Halozyme Therapeutics Stock Up 1.7%

Shares of Halozyme Therapeutics stock traded up $0.87 on Tuesday, reaching $52.89. 1,386,827 shares of the company were exchanged, compared to its average volume of 1,744,082. The stock's 50 day moving average price is $55.92 and its 200-day moving average price is $56.54. The company has a debt-to-equity ratio of 3.13, a current ratio of 8.39 and a quick ratio of 7.30. Halozyme Therapeutics, Inc. has a 1-year low of $42.01 and a 1-year high of $70.51. The company has a market cap of $6.52 billion, a P/E ratio of 14.07, a price-to-earnings-growth ratio of 0.35 and a beta of 1.19.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last posted its quarterly earnings results on Tuesday, May 6th. The biopharmaceutical company reported $1.11 EPS for the quarter, topping the consensus estimate of $0.98 by $0.13. Halozyme Therapeutics had a net margin of 44.76% and a return on equity of 136.91%. The company had revenue of $264.86 million during the quarter, compared to analysts' expectations of $231.21 million. During the same quarter in the previous year, the business posted $0.79 EPS. The firm's revenue was up 35.2% on a year-over-year basis. As a group, equities analysts forecast that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current year.

Wall Street Analysts Forecast Growth

HALO has been the topic of several recent analyst reports. Benchmark lowered shares of Halozyme Therapeutics from a "strong-buy" rating to a "hold" rating in a report on Wednesday, May 7th. Leerink Partners lowered Halozyme Therapeutics from a "market perform" rating to an "underperform" rating and set a $47.00 price target for the company. in a research report on Tuesday, May 13th. JPMorgan Chase & Co. lifted their price objective on Halozyme Therapeutics from $55.00 to $58.00 and gave the company a "neutral" rating in a research note on Monday, April 21st. Leerink Partnrs lowered Halozyme Therapeutics from a "hold" rating to a "strong sell" rating in a research note on Tuesday, May 13th. Finally, Wells Fargo & Company raised their target price on Halozyme Therapeutics from $60.00 to $65.00 and gave the company an "equal weight" rating in a report on Wednesday, May 7th. Two analysts have rated the stock with a sell rating, six have issued a hold rating and four have given a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of "Hold" and an average target price of $61.90.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.